---
title: "Varegacestat (AL102) in Desmoid tumors: Heterogeneity of treatment effect"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Heterogeneity of treatment effect. Topics: RINGSIDE Part B progression-free survival across subgroups, RINGSIDE Part A objective response by subgroup, DeFi progression-free survival across prespecified subgroups, Baseline pain control and pain response with nirogacestat, and 6 further topics. 10 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### RINGSIDE Part B progression-free survival across subgroups

> “PFS consistently favored VAR in all subgroups analyzed.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “The PFS benefit observed with varegacestat vs. placebo was consistent across key subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

> “Consistent PFS Benefit with Varegacestat Across Subgroups”
> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”
> “Hazard ratio estimated from Cox proportional hazards model stratified by tumor location (intra-abdominal vs extra-abdominal)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “PFS consistently favored varegacestat in all subgroups analyzed”
> “Age ≤30 / >30 years”
> “Tumor location intra-/extra-abdominal”
> “CTNNB1 mutation (S45F+S45P T41A)”
> “Baseline tumor size >10 / ≤10 cm”
> “Prior systemic DT therapy (yes/no)”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-2.2.2.3-2"></a>

### RINGSIDE Part A objective response by subgroup

> “We performed descriptive analyses of objective response rate (ORR) in the following subgroups with at least 5 participants: age (≤40 years vs. >40 years), tumor size (<70 mm vs. ≥70 mm), prior lines of therapy (0, 1, or 2+), tumor location (intra-abdominal vs. extra-abdominal) and mutational biomarkers (APC vs CTNNB1). Subgroups were analyzed by pooling across dose regimens.”
> “ORR ranged from 43% to 78% across age, tumor size, prior therapy, tumor location and mutation subgroups (Table). Response rates were comparable across all subgroups examined.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

| Subgroup | ORR, responders (%) |
| --- | --- |
| Age | “Age ≤40 years (n=22) vs. >40 years (n=14)” “13 (59) vs. 10 (71)” |
| Tumor size | “Tumor size <70 mm (n=18) vs. ≥70 mm (n=14)” “13 (72) vs. 9 (64)” |
| Prior lines of therapy | “Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9)” “6 (55), 10 (63), 7 (78)” |
| Tumor location | “Intra-abdominal (n=9) vs. extra-abdominal (n=27)” “4 (44) vs. 19 (70)” |
| Mutation | “APC (n=7) vs CTNNB1 (n=19) mutation” “3 (43) vs. 13 (68)” |

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-2.2.2.3-3"></a>

### DeFi progression-free survival across prespecified subgroups

> “Between-group differences in progression-free survival were consistent across prespecified subgroups.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.3-4"></a>

### Baseline pain control and pain response with nirogacestat

> “At technical engagement, the company clarified that 39% of people in the nirogacestat group and 43% in the placebo group in De-Fi had uncontrolled pain at baseline. The company provided a post-hoc analysis for subgroups with controlled and uncontrolled pain at baseline. It reported that both groups showed clinically meaningfully improved pain at cycle 10 (each cycle in De-Fi was 28 days). But the improvement was greater in the group that had uncontrolled pain at baseline.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.3-5"></a>

### CTNNB1 S45F mutation and recurrence after surgery

> “The estimated 5-year recurrence-free survival rate was 23% (95% CI, 10 to 40%) for patients with 45F mutation compared to 57% (95% CI, 43 to 69%), and 65% (95% CI, 38 to 83%) for 41A mutation and nonmutated CTNNB1, respectively.”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

> “The estimated 3-year and 5-year RFS rates were 0.49 and 0.45, respectively, for patients who had tumors with the S45F mutation; 0.91 and 0.91, respectively, for patients who had wild-type tumors; and 0.70 and 0.66, respectively, for all others”
> “This series confirmed that primary, completely resected, sporadic DTs with the S45F mutation have a greater tendency for local recurrence.”

Source: [Colombo et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23913621/)

<a id="topic-2.2.2.3-6"></a>

### CTNNB1 mutation, tumor size, and location during active surveillance

> “In multivariable analysis, larger tumor size, mutation type, and tumor locations were associated with lower TFS. The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.”
> “Initial tumor size, CTNNB1 mutation, and location should be factored into the initial decision-making process.”

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)

<a id="topic-2.2.2.3-7"></a>

### Tumor location and outcome of surgery compared with a wait-and-see approach

> “The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).”

Source: [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)

<a id="topic-2.2.2.3-8"></a>

### Age, tumor site, and tumor size and recurrence after resection

> “In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).”
> “Systemic therapies may be appropriate for young patients with large, extremity desmoids, but surgery alone is curative for most abdominal wall lesions.”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.2.3-9"></a>

### Familial adenomatous polyposis-associated and intra-abdominal desmoid tumors

> “FAP-associated DT (Gardner syndrome) seems to be more aggressive and multifocal and, therefore, tends to be treated more aggressively in terms of medical management.”
> “FAP patients should be jointly managed by sarcoma specialists and experts in gastrointestinal cancer.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “They stated that for extra-abdominal desmoid tumours, which are usually sporadic, chemotherapy would be used to manage symptoms.”
> “Intra-abdominal desmoid tumours, which are usually FAP-associated, are less likely to cause pain, and treatment focuses more on removing obstructions. In these cases, fewer people have chemotherapy and people are more likely to have surgery. One clinical expert noted that FAP-associated desmoid tumours that are treated with chemotherapy have good responses.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.3-10"></a>

### Age and reproductive potential in the selection of a gamma secretase inhibitor

> “One key factor influencing treatment selection is patient age and reproductive potential. For women of childbearing age, providers weigh the potential risk of ovarian toxicity associated with nirogacestat.”
> “That is a much harder decision for a younger woman. For older women or male patients, the decision is more straightforward.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

> “Varegacestat 56% | Placebo 5% of premenopausal women”
> “No women discontinued varegacestat due to ovarian toxicity”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
